ArticleJournal of neuro-oncology2019
Lack of B and T cell reactivity towards IDH1
Article in Journal of neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Pooled it
- The potential applications of peptide-loading complex in cancer treatment.Frontiers in immunology · 2025Review
- Analysis of glutathione Stransferase mu class 5 gene methylation as a prognostic indicator in low-grade gliomas.Technology and health care : official journal of the European Society for Engineering and Medicine · 2024Article
- Arachidonate lipoxygenases 5 is a novel prognostic biomarker and correlates with high tumor immune infiltration in low-grade glioma.Frontiers in genetics · 2023Article
- CCNB2 is a novel prognostic factor and a potential therapeutic target in low-grade glioma.Bioscience reports · 2022Article
- NCAPG as a Novel Prognostic Biomarker in Glioma.Frontiers in oncology · 2022Article
- Emerging targets for anticancer vaccination: IDH.ESMO open · 2021Review
- Methylation and Expression of the Exercise-Related TLR1 Gene Is Associated With Low Grade Glioma Prognosis and Outcome.Frontiers in molecular biosciences · 2021Article
- Identification of Critical mBioMed research international · 2021Article
- Current biomarker-associated procedures of cancer modeling-a reference in the context of IDH1 mutant glioma.Cell death & disease · 2020Review
- Needle in a Haystack: The Naïve Repertoire as a Source of T Cell Receptors for Adoptive Therapy with Engineered T Cells.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMutations in the isocitrate dehydrogenase-1 gene (IDH1) occur at high frequency in grade II-III gliomas (LGGs). IDH1 mutations are somatic, missense and heterozygous affecting codon 132 in the catalytic pocket of the enzyme. In LGG, most mutations (90%) result in an arginine to histidine substitution (IDH1
methodsSera from IDH1
resultsDespite high sensitivity of our assay, we failed to detect IDH1
conclusionsThe absence of both humoral and cellular responses in blood and tumors of LGG patients indicates that IDH1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.